These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

858 related items for PubMed ID: 29043400

  • 21. CDKN2A homozygous deletion is a strong adverse prognosis factor in diffuse malignant IDH-mutant gliomas.
    Appay R, Dehais C, Maurage CA, Alentorn A, Carpentier C, Colin C, Ducray F, Escande F, Idbaih A, Kamoun A, Marie Y, Mokhtari K, Tabouret E, Trabelsi N, Uro-Coste E, Delattre JY, Figarella-Branger D, POLA Network.
    Neuro Oncol; 2019 Dec 17; 21(12):1519-1528. PubMed ID: 31832685
    [Abstract] [Full Text] [Related]

  • 22. RNA editing-based classification of diffuse gliomas: predicting isocitrate dehydrogenase mutation and chromosome 1p/19q codeletion.
    Chen SC, Lo CM, Wang SH, Su EC.
    BMC Bioinformatics; 2019 Dec 24; 20(Suppl 19):659. PubMed ID: 31870275
    [Abstract] [Full Text] [Related]

  • 23. Perfusion and diffusion MRI signatures in histologic and genetic subtypes of WHO grade II-III diffuse gliomas.
    Leu K, Ott GA, Lai A, Nghiemphu PL, Pope WB, Yong WH, Liau LM, Cloughesy TF, Ellingson BM.
    J Neurooncol; 2017 Aug 24; 134(1):177-188. PubMed ID: 28547590
    [Abstract] [Full Text] [Related]

  • 24. Radiological characteristics based on isocitrate dehydrogenase mutations and 1p/19q codeletion in grade II and III gliomas.
    Yamauchi T, Ohno M, Matsushita Y, Takahashi M, Miyakita Y, Kitagawa Y, Kondo E, Tsushita N, Satomi K, Yoshida A, Ichimura K, Narita Y.
    Brain Tumor Pathol; 2018 Jul 24; 35(3):148-158. PubMed ID: 29922974
    [Abstract] [Full Text] [Related]

  • 25. The Diagnostic Value of Conventional MRI and CT Features in the Identification of the IDH1-Mutant and 1p/19q Co-Deletion in WHO Grade II Gliomas.
    Zhao K, Sun G, Wang Q, Xue Z, Liu G, Xia Y, Yao A, Zhao Y, You N, Yang C, Xu B.
    Acad Radiol; 2021 Jul 24; 28(7):e189-e198. PubMed ID: 32359929
    [Abstract] [Full Text] [Related]

  • 26. Voxel-based 18F-FET PET segmentation and automatic clustering of tumor voxels: A significant association with IDH1 mutation status and survival in patients with gliomas.
    Blanc-Durand P, Van Der Gucht A, Verger A, Langen KJ, Dunet V, Bloch J, Brouland JP, Nicod-Lalonde M, Schaefer N, Prior JO.
    PLoS One; 2018 Jul 24; 13(6):e0199379. PubMed ID: 29953478
    [Abstract] [Full Text] [Related]

  • 27. Radiogenomics Provides Insights into Gliomas Demonstrating Single-Arm 1p or 19q Deletion.
    Lasocki A, Buckland ME, Molinaro T, Xie J, Gaillard F.
    AJNR Am J Neuroradiol; 2023 Nov 24; 44(11):1270-1274. PubMed ID: 37884300
    [Abstract] [Full Text] [Related]

  • 28. Allelic losses at 1p36 and 19q13 in gliomas: correlation with histologic classification, definition of a 150-kb minimal deleted region on 1p36, and evaluation of CAMTA1 as a candidate tumor suppressor gene.
    Barbashina V, Salazar P, Holland EC, Rosenblum MK, Ladanyi M.
    Clin Cancer Res; 2005 Feb 01; 11(3):1119-28. PubMed ID: 15709179
    [Abstract] [Full Text] [Related]

  • 29. Diffuse gliomas classified by 1p/19q co-deletion, TERT promoter and IDH mutation status are associated with specific genetic risk loci.
    Labreche K, Kinnersley B, Berzero G, Di Stefano AL, Rahimian A, Detrait I, Marie Y, Grenier-Boley B, Hoang-Xuan K, Delattre JY, Idbaih A, Houlston RS, Sanson M.
    Acta Neuropathol; 2018 May 01; 135(5):743-755. PubMed ID: 29460007
    [Abstract] [Full Text] [Related]

  • 30. Comparison of [18F]Fluoroethyltyrosine PET and Sodium MRI in Cerebral Gliomas: a Pilot Study.
    Shymanskaya A, Worthoff WA, Stoffels G, Lindemeyer J, Neumaier B, Lohmann P, Galldiks N, Langen KJ, Shah NJ.
    Mol Imaging Biol; 2020 Feb 01; 22(1):198-207. PubMed ID: 30989437
    [Abstract] [Full Text] [Related]

  • 31. Individualized discrimination of tumor progression from treatment-related changes in different types of adult-type diffuse gliomas using [11C]methionine PET.
    Chen Q, Wang K, Ren X, Zhao X, Chen Q, Fan D, Zhang S, Li X, Ai L.
    J Neurooncol; 2023 Dec 01; 165(3):547-559. PubMed ID: 38095773
    [Abstract] [Full Text] [Related]

  • 32. Prediction of IDH1-Mutation and 1p/19q-Codeletion Status Using Preoperative MR Imaging Phenotypes in Lower Grade Gliomas.
    Park YW, Han K, Ahn SS, Bae S, Choi YS, Chang JH, Kim SH, Kang SG, Lee SK.
    AJNR Am J Neuroradiol; 2018 Jan 01; 39(1):37-42. PubMed ID: 29122763
    [Abstract] [Full Text] [Related]

  • 33. Diagnostic Performance of [11C]Methionine Positron Emission Tomography in Newly Diagnosed and Untreated Glioma Based on the Revised World Health Organization 2016 Classification.
    Nakajo K, Uda T, Kawashima T, Terakawa Y, Ishibashi K, Tsuyuguchi N, Tanoue Y, Nagahama A, Uda H, Koh S, Sasaki T, Ohata K, Kanemura Y, Goto T.
    World Neurosurg; 2021 Apr 01; 148():e471-e481. PubMed ID: 33444827
    [Abstract] [Full Text] [Related]

  • 34. A nuclear transport-related gene signature combined with IDH mutation and 1p/19q codeletion better predicts the prognosis of glioma patients.
    Zhu Z, Lan Y, Wang L, Ge J, Wang J, Liu F, He Z, Zhang H, Luo M, Lin D, Tan Y, Xu Y, Luo T.
    BMC Cancer; 2020 Nov 09; 20(1):1072. PubMed ID: 33167941
    [Abstract] [Full Text] [Related]

  • 35. 18F-FDOPA PET for the Noninvasive Prediction of Glioma Molecular Parameters: A Radiomics Study.
    Zaragori T, Oster J, Roch V, Hossu G, Chawki MB, Grignon R, Pouget C, Gauchotte G, Rech F, Blonski M, Taillandier L, Imbert L, Verger A.
    J Nucl Med; 2022 Jan 09; 63(1):147-157. PubMed ID: 34016731
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. High-grade gliomas with isocitrate dehydrogenase wild-type and 1p/19q codeleted: Atypical molecular phenotype and current challenges in molecular diagnosis.
    Zheng L, Zhang M, Hou J, Gong J, Nie L, Chen X, Zhou Q, Chen N.
    Neuropathology; 2020 Dec 09; 40(6):599-605. PubMed ID: 32761642
    [Abstract] [Full Text] [Related]

  • 38. 1p/19q co-deleted fibrillary astrocytomas: Not everything that is co-deleted is an oligodendroglioma.
    Andrews C, Prayson RA.
    Ann Diagn Pathol; 2020 Jun 09; 46():151519. PubMed ID: 32305004
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Analysis of IDH mutation, 1p/19q deletion, and PTEN loss delineates prognosis in clinical low-grade diffuse gliomas.
    Sabha N, Knobbe CB, Maganti M, Al Omar S, Bernstein M, Cairns R, Çako B, von Deimling A, Capper D, Mak TW, Kiehl TR, Carvalho P, Garrett E, Perry A, Zadeh G, Guha A, Sidney Croul.
    Neuro Oncol; 2014 Jul 09; 16(7):914-23. PubMed ID: 24470545
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 43.